Compare BFS & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BFS | CMPS |
|---|---|---|
| Founded | 1993 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 770.9M | 662.5M |
| IPO Year | 1993 | 2020 |
| Metric | BFS | CMPS |
|---|---|---|
| Price | $31.87 | $6.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $16.86 |
| AVG Volume (30 Days) | 67.4K | ★ 1.5M |
| Earning Date | 02-27-2026 | 02-26-2026 |
| Dividend Yield | ★ 7.46% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $282,618,000.00 | N/A |
| Revenue This Year | $8.14 | N/A |
| Revenue Next Year | $5.75 | N/A |
| P/E Ratio | $27.73 | ★ N/A |
| Revenue Growth | ★ 5.61 | N/A |
| 52 Week Low | $29.16 | $2.25 |
| 52 Week High | $37.89 | $8.20 |
| Indicator | BFS | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 53.43 | 45.39 |
| Support Level | $30.77 | $6.55 |
| Resistance Level | $32.26 | $7.45 |
| Average True Range (ATR) | 0.62 | 0.42 |
| MACD | -0.07 | -0.11 |
| Stochastic Oscillator | 57.26 | 11.90 |
Saul Centers Inc is a self-managed real estate investment trust which invests in, operates and develops retail and commercial properties. The company's portfolio includes community and neighbourhood shopping centres, office properties, and mixed-use properties. Properties are located in the Washington, D.C. and Batlimore metropolitan areas. Saul Centers operates through two business segments: shopping centers, which contribute the maximum portion of total revenue; and mixed-use properties. Maximum tenants include grocery stores, discount department stores, and drug stores.
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.